Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder
Tóm tắt
Từ khóa
Tài liệu tham khảo
Andén, 1973, Baclofen and lithium in Huntington’s chorea, Lancet, 2, 93, 10.1016/S0140-6736(73)93285-6
Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, Young LT, and Yatham LN (2009) 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34:263–271.
Aoki, 1997, Induction of Bip mRNA upon programmed cell death of differentiated PC12 cells as well as rat sympathetic neurons, J Biochem, 121, 122, 10.1093/oxfordjournals.jbchem.a021554
Baumgardner, 1995, Specification of the neurobehavioral phenotype in males with fragile X syndrome, Pediatrics, 95, 744, 10.1542/peds.95.5.744
Biermann, 2011, Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells, Mol Vis, 17, 395
Brinkman, 1984, Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia, Biol Psychiatry, 19, 157
Carman, 1974, Letter: Huntington’s chorea treated with lithium carbonate, Lancet, 1, 811, 10.1016/S0140-6736(74)92881-5
Chang, 2003, Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review), Int J Oncol, 22, 469
Chateauvieux, 2010, Molecular and therapeutic potential and toxicity of valproic acid, J Biomed Biotechnol, 2010, 2010, 10.1155/2010/479364
Chuang DM, Wang Z and Chiu CT (2011) GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Frontiers in Molecular Neuroscience 4:15.
Dikmen, 2000, Neuropsychological effects of valproate in traumatic brain injury: a randomized trial, Neurology, 54, 895, 10.1212/WNL.54.4.895
Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, Reis SA, Klein PS, Mazitschek R, et al. (2010) Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett 2:39–42.
Feng, 1979, The necessity for a collection development policy statement, Libr Resour Tech Serv, 23, 39
Foerster, 1977, [Lithium therapy of extrapyramidal movement disorders-an attempt (author’s transl)], Nervenarzt, 48, 228
Fulceri, 2011, Autophagy activation in glutamate-induced motor neuron loss, Arch Ital Biol, 149, 101
Gafni, 2002, Calpain activation in Huntington’s disease, J Neurosci, 22, 4842, 10.1523/JNEUROSCI.22-12-04842.2002
Goodwin FK Jamison KR (2007) Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Oxford University Press, New York.
Gould, 2005, Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs, Neuropsychopharmacology, 30, 1223, 10.1038/sj.npp.1300731
Hegde, 2011, Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease, Biochim Biophys Acta, 1809, 128, 10.1016/j.bbagrm.2010.07.006
Hunsberger, 2012, Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia, Am J Transl Res, 4, 316
Inestrosa, 2000, Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity, Acta Neurol Scand Suppl, 176, 53, 10.1034/j.1600-0404.2000.00308.x
Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Fron Mol Neurosci 4:16.
Khairova, 2012, Effects of lithium on oxidative stress parameters in healthy subjects, Mol Med Report, 5, 680
Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, and Eldar-Finkelman H (2004) Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosc 24:237–245.
Kostrouchová, 2007, Valproic acid, a molecular lead to multiple regulatory pathways, Folia Biol (Praha), 53, 37
Leonard, 1974, Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington’s chorea, Lancet, 2, 1208, 10.1016/S0140-6736(74)90847-2
Leroy, 2010, Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology, J Alzheimers Dis, 19, 705, 10.3233/JAD-2010-1276
Leyhe, 2009, Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease, J Alzheimers Dis, 16, 649, 10.3233/JAD-2009-1004
Li Q, Li H, Roughton K, Wang X, Kroemer G, Blomgren K and Zhu C (2010a) Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell death & disease 1:e56.
Lyoo, 2010, Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study, Neuropsychopharmacology, 35, 1743, 10.1038/npp.2010.41
Macdonald, 1995, Antiepileptic drug mechanisms of action, Epilepsia, 36, S2, 10.1111/j.1528-1157.1995.tb05996.x
Manyam, 1973, Lithium carbonate in Huntington’s chorea, Lancet, 1, 1010, 10.1016/S0140-6736(73)91664-4
Mattsson, 1973, Huntington’s chorea and lithium therapy, Lancet, 1, 718, 10.1016/S0140-6736(73)91500-6
Mines MA and Jope RS (2011) Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Frontiers in molecular neuroscience 4:35.
Muñoz-Montaño, 1999, Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer’s Disease, J Alzheimers Dis, 1, 361, 10.3233/JAD-1999-1602
Neri, 2002, The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system, Biochim Biophys Acta, 1584, 73, 10.1016/S1388-1981(02)00300-1
Newton, 2003, Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors, J Neurosci, 23, 10841, 10.1523/JNEUROSCI.23-34-10841.2003
Ozaki, 1997, Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain, J Neurochem, 69, 2336, 10.1046/j.1471-4159.1997.69062336.x
Park HJ, Kang WS, Paik JW, and Kim JW (2012) Effect of valproic acid through regulation of NMDA receptor-ERK signaling in sleep deprivation rats. J Mol Neurosci 47:554–558.
Pérez, 2003, Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model, J Alzheimers Dis, 5, 301, 10.3233/JAD-2003-5405
Rao JS and Rapoport SI (2009) Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2:207–214.
Schenk, 1974, Letter: Huntington’s chorea and levodopa, Lancet, 1, 364, 10.1016/S0140-6736(74)93130-4
Seidensticker, 2000, Biochemical interactions in the wnt pathway, Biochim Biophys Acta, 1495, 168, 10.1016/S0167-4889(99)00158-5
Selkoe, 2001, Alzheimer’s disease: genes, proteins, and therapy, Physiol Rev, 81, 741, 10.1152/physrev.2001.81.2.741
Senatorov, 2007, Lithium protects against quinolinic-acid excitotoxicity in rat cortico-striatal organotypic culture, Int J Neuroprotect Neuroregen, 3, 122
Shirayama, 2002, Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression, J Neurosci, 22, 3251, 10.1523/JNEUROSCI.22-08-03251.2002
Silva, 2007, Lithium prevents stress-induced reduction of vascular endothelium growth factor levels, Neurosci Lett, 429, 33, 10.1016/j.neulet.2007.09.062
Sofola, 2010, Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer’s disease, PLoS Genet, 6, 6, 10.1371/journal.pgen.1001087
Sovner, 1989, The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders, J Clin Psychiatry, 50, 40
Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, and Brooks DJ (1996) Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 11:167-173.
Torrioli, 2010, Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys, Am J Med Genet A, 152A, 1420, 10.1002/ajmg.a.33484
Torrioli, 2008, A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys, Am J Med Genet A, 146, 803, 10.1002/ajmg.a.32268
Trojanowski, 1995, Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions: focusing on phosphatases, FASEB J, 9, 1570, 10.1096/fasebj.9.15.8529836
Wang, 1999, Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78, Mol Pharmacol, 55, 521
Wheelock, 2003, Predictors of nursing home placement in Huntington disease, Neurology, 60, 998, 10.1212/01.WNL.0000052992.58107.67
Woo NH and Lu B (2006) Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 12:43–56.
Xu, 2009, TRPM2 variants and bipolar disorder risk: confirmation in a family-based association study, Bipolar Disord, 11, 1, 10.1111/j.1399-5618.2008.00655.x
Xu, 2006, Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder, Am J Med Genet B Neuropsychiatr Genet, 141B, 36, 10.1002/ajmg.b.30239
Yatham, 2004, Newer anticonvulsants in the treatment of bipolar disorder, J Clin Psychiatry, 65, 28
Yu F, Zhang Y and Chuang DM (2012b) Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 29:2342–2351.
Zhang, 2011, Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer’s disease transgenic mouse model, J Alzheimers Dis, 24, 739, 10.3233/JAD-2011-101875